Načítá se...
Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice
BACKGROUND: Nivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patter...
Uloženo v:
| Vydáno v: | Urol Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6863156/ https://ncbi.nlm.nih.gov/pubmed/28259541 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2017.01.017 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|